In this articleNOVO.B-DKA box of Ozempic sits on a table in North Tyneside, Britain, Oct. 31, 2023.Lee Smith | ReutersDanish pharmaceutical giant Novo Nordisk said Wednesday it is lowering its growth expectations for its key obesity and diabetes treatments.Net profit for the quarter came in at 20 billion Danish kroner ($3.1 billion) in line with the 20.12 billion Danish kroner anticipated by analysts in a FactSet poll.Diabetes and obesity care were a key growth driver following the uptake of Wegovy and Ozem ...